SLRX Salarius Pharmaceuticals Inc
Price (delayed)
$1.59
Market cap
$2.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.85
Enterprise value
-$981,383
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment
Highlights
The debt has plunged by 100% from the previous quarter
The EPS has soared by 89% YoY and by 46% from the previous quarter
SLRX's equity has shrunk by 72% YoY and by 35% QoQ
The quick ratio has declined by 21% since the previous quarter and by 13% year-on-year
Key stats
What are the main financial stats of SLRX
Market
Valuations
Earnings
Shares outstanding
1.44M
Market cap
$2.29M
Enterprise value
-$981,383
Price to earnings (P/E)
N/A
Price to book (P/B)
0.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$6.46M
EBITDA
-$6.46M
Free cash flow
-$7.69M
Per share
Balance sheet
Liquidity
EPS
-$10.85
Free cash flow per share
-$12.8
Book value per share
$3.98
Revenue per share
$0
TBVPS
$5.92
Total assets
$3.55M
Total liabilities
$1.18M
Debt
$0
Equity
$2.38M
Working capital
$2.34M
Debt to equity
0
Current ratio
2.98
Quick ratio
2.78
Net debt/EBITDA
0.51
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-110.4%
Return on equity
-148.6%
Return on invested capital
N/A
Return on capital employed
-272.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLRX stock price
How has the Salarius Pharmaceuticals stock price performed over time
Intraday
1.92%
1 week
5.3%
1 month
-16.32%
1 year
-76.82%
YTD
-69.42%
QTD
-33.19%
Financial performance
How have Salarius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$6.74M
Net income
-$6.46M
Gross margin
N/A
Net margin
N/A
The operating income has soared by 78% YoY and by 27% QoQ
SLRX's net income has surged by 78% year-on-year and by 28% since the previous quarter
Growth
What is Salarius Pharmaceuticals's growth rate over time
Valuation
What is Salarius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 89% YoY and by 46% from the previous quarter
SLRX's equity has shrunk by 72% YoY and by 35% QoQ
The P/B is 44% lower than the 5-year quarterly average of 0.7 and 22% lower than the last 4 quarters average of 0.5
Efficiency
How efficient is Salarius Pharmaceuticals business performance
SLRX's ROE is up by 49% YoY and by 2.4% from the previous quarter
The ROA is up by 48% YoY
Dividends
What is SLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLRX.
Financial health
How did Salarius Pharmaceuticals financials performed over time
Salarius Pharmaceuticals's total assets has shrunk by 71% YoY and by 27% QoQ
The company's total liabilities has shrunk by 68% YoY and by 4.5% QoQ
The debt is 100% less than the equity
The debt has plunged by 100% from the previous quarter
SLRX's debt to equity has plunged by 100% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.